

# CITATION REPORT

List of articles citing

Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome

DOI: 10.1080/14737175.2021.1834383

Expert Review of Neurotherapeutics, 2021, 21, 99-110.

**Source:** <https://exaly.com/paper-pdf/77813011/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
15	Novel therapeutic options for Dravet and Lennox-Gastaut syndrome. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 1191-1194	4.3	2
14	The Chemistry of Cannabis and Cannabinoids. <i>Australian Journal of Chemistry</i> , <b>2021</b> , 74, 369	1.2	5
13	Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 561-576	4.1	4
12	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. <i>CNS Drugs</i> , <b>2021</b> , 35, 265-281	6.7	7
11	Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 637801	5.6	4
10	Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 673135	4.1	5
9	Comorbidities in Dravet Syndrome and Lennox-Gastaut Syndrome. <i>SN Comprehensive Clinical Medicine</i> , <b>2021</b> , 3, 2167-2179	2.7	1
8	In Silico and In Vitro Analysis of Major Cannabis-Derived Compounds as Fatty Acid Amide Hydrolase Inhibitors. <i>Molecules</i> , <b>2020</b> , 26,	4.8	4
7	Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients. <i>Seizure: the Journal of the British Epilepsy Association</i> , <b>2021</b> , 92, 238-243	3.2	2
6	Palmitoylethanolamide: A Potential Alternative to Cannabidiol. <i>Journal of Dietary Supplements</i> , <b>2021</b> , 1-26	2.3	5
5	Cannabidiol and substance use disorder: Dream or reality.. <i>Neuropharmacology</i> , <b>2022</b> , 207, 108948	5.5	1
4	Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs. 9,		1
3	Cannabidiol inhibits microglia activation and mitigates neuronal damage induced by kainate in an in-vitro seizure model. <b>2022</b> , 174, 105895		1
2	An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. <b>2023</b> , 16, 257-266		2
1	Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis.		0